1.40
+15.70%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Myomo
From its filings with the US Securities and Exchange Commission
Myomo is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on NYSE under the ticker MYO. The SEC classifies its business as orthopedic, prosthetic & surgical appliances & supplies. In the fiscal year to 31 December 2025, it reported revenue of $40.9m and a net loss of $15.6m. At that date it held total assets of $38.6m and shareholders' equity of $11.4m.
Our goal is to help individuals who have suffered partial paralysis and can no longer support or move their arm or hand despite the best efforts of surgeons and rehabilitation therapists.
Our solution, the MyoPro custom fabricated limb orthosis, is for the upper limbs. The concept was originally pioneered in the 1960s, refined in the labs of the Massachusetts Institute of Technology, or MIT, and made commercially feasible through our efforts. Partial paralysis is severe muscle weakness or loss of voluntary movement in one or more parts of the body. The MyoPro is listed in the United States with the FDA as a Class II (510(k)-exempt) device (Biofeedback Device). We believe it is the only device commercially available in the United States that is able to help neuromuscular-impaired people who have been through therapy and have been left with partial paralysis regain movement in weak arms and hands using their own muscle signals. The device consists of a portable arm brace made of a lightweight metal and includes advanced signal processing software, non-invasive sensors, small motors, a lightweight battery unit, and 3D printed materials which are unique for each patient's arm and hand measurements. The product is worn to support the arm and hand and as a functional aid for reaching and grasping and has also been shown to have therapeutic benefits for some users to increase motor control.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 12 Jun 2017
- Employees
- 100
- Website
- myomo.com ↗
- Head office
- 137 PORTLAND STREET, BOSTON, MA, 02114
- Incorporated in
- DE
- Classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Paul GudonisChairman of the Board, President, Chief Executive Officer, since 2011$1.2m
- Mr. David HenryChief Financial Officer$784,166
- Dr. Harry KovelmanChief Medical Officer$695,112
- Mr. Micah MitchellChief Commercial Officer$459,434
- Mr. Thomas KirkLead Independent Director$99,500
- Mr. Thomas CrowleyIndependent Director$99,500
- Ms. Heather GetzIndependent Director$85,750
- Dr. Milton MorrisIndependent Director$100,750
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Myomo Inc. develops the MyoPro product line for neuromuscular disorders in the Health Care sector.
- The company employs 100 full-time employees in Boston, Massachusetts, supporting medical robotics innovation.
- MyoPro enables self-initiated limb control using muscle signals for ADLs in home and community settings.
Weaknesses
- Myomo Inc. has a limited workforce of 100 employees in the Health Care industry.
- The company relies on insurance billing for revenue, which may cause payment delays.
- Myomo's product line focuses solely on upper limb orthotics without broader medical device expansion.
Opportunities
- Expanding MyoPro to new countries like Germany could increase market reach in Europe.
- Growing demand for neuromuscular disorder solutions in the Health Care sector presents opportunities.
- The Health Care industry's focus on functional improvement aligns with MyoPro's capabilities.
Threats
- Insurance billing complexities may hinder revenue growth in the Health Care sector.
- Competition from other Health Care companies could impact Myomo's market position.
- Neuromuscular disorder treatments face evolving regulatory requirements in the US.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.